OBIO ORCHESTRA BIOMED HOLDINGS INC

Orchestra BioMed to Participate in Jefferies Global Healthcare Conference

Orchestra BioMed to Participate in Jefferies Global Healthcare Conference

NEW HOPE, Pa., May 22, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at the Jefferies Global Healthcare Conference being held in New York, NY, June 4-6, 2024.

Details of the presentation are below.

Format: Fireside Chat

Date: Wednesday, June 5, 2024

Time: 4:00 PM ET (Track 1)

Webcast:

A replay of the webcast will be available on the Events section of the Orchestra BioMed website for 90 days following the presentation.

About Orchestra BioMed

Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Orchestra BioMed’s partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products it develops. Orchestra BioMed’s lead product candidate is atrioventricular interval modulation (AVIM) therapy (also known as BackBeat Cardiac Neuromodulation Therapy (CNT™)) for the treatment of hypertension, a significant risk factor for death worldwide. Orchestra BioMed is also developing Virtue® Sirolimus AngioInfusion™ Balloon (SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Orchestra BioMed has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for development and commercialization of AVIM therapy for the treatment of hypertension in pacemaker-indicated patients, and a strategic partnership with Terumo, a global leader in medical technology, for development and commercialization of Virtue SAB for the treatment of artery disease. For further information about Orchestra BioMed, please visit , and follow us on .

Investor Contact:

Bob Yedid

LifeSci Advisors

516-428-8577

  

Media Contact:

Kelsey Kirk-Ellis

Orchestra BioMed

484-682-4892



EN
22/05/2024

Underlying

OBIOORCHESTRA BIOMED HOLDINGS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ORCHESTRA BIOMED HOLDINGS INC

 PRESS RELEASE
Free
OBIO ORCHESTRA BIOME...

Orchestra BioMed Announces Pricing of $40 Million Public Offering

Orchestra BioMed Announces Pricing of $40 Million Public Offering NEW HOPE, Pa., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, announced today the pricing of an underwritten public offering of 9,413,637 shares of its common stock at a price to the public of $2.75 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 5,136,363 shares of its common stock at a price to t...

4h 1 EN
 PRESS RELEASE
Free
OBIO ORCHESTRA BIOME...

Orchestra BioMed Announces Proposed Public Offering

Orchestra BioMed Announces Proposed Public Offering NEW HOPE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, announced today that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock (the “Offering”). All of the securities are being offered by the Company. In addition,...

19h / 57m 1 EN
 PRESS RELEASE
Free
OBIO ORCHESTRA BIOME...

Ligand and Medtronic Commit $70 Million in Strategic Capital to Orches...

Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed • Ligand to invest $35 million in exchange for a tiered royalty on future sales of Orchestra’s AVIM therapy and Virtue SAB and an additional $5 million in an equity private placement • Medtronic to invest $10 million in an equity private placement and an additional $20 million in a secured subordinated promissory note convertible to prepaid revenue share • Medtronic and Orchestra BioMed expand strategic collaboration to provide pathway for development of AVIM therapy-enabled leadless pacemakers NEW HOPE, Pa....

19h / 58m 1 EN
 PRESS RELEASE
Free
OBIO ORCHESTRA BIOME...

Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for ...

Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025 Presentation underscores unique potential for atrioventricular interval modulation (“AVIM”) therapy to manage blood pressure in older, high-risk patients who have indicators of diastolic dysfunction and progression to heart failure with preserved ejection fraction (“HFpEF”)Hypertensive heart disease represents over 7.7 million U.S. patients, the same population with hypertension and elevated cardiovascular risk cited in the recent FDA Breakthrough Device Designation (“BDD”)...

June 18, 2025 1 EN
 PRESS RELEASE
Free
OBIO ORCHESTRA BIOME...

Orchestra BioMed Reports First Quarter 2025 Financial Results and High...

Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones FDA Breakthrough Device Designation Awarded to AVIM Therapy FDA IDE Approved for Virtue SAB U.S. Pivotal Trial for Launch NEW HOPE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced financial results for the first quarter ended March 31, 2025, and provided a business updat...

May 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch